Resistance to Antiplatelet Drugs: Is It Real or Relevant?

Catheterization and Cardiovascular Interventions

Volumn 62, Issue 1, 2004, Pages 43-45

  Berger, Peter B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

BRACHYTHERAPY; CORONARY ARTERY DISEASE; DRUG EFFECT; EDITORIAL; ENZYME INHIBITION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; STENT THROMBOSIS; STROKE; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BLOOD VESSEL PROSTHESIS IMPLANTATION; BRACHYTHERAPY; CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG RESISTANCE; GRAFT OCCLUSION, VASCULAR; HUMANS; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TIME FACTORS;

EID: 2342466795     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20031     Document Type: Editorial

References (25)

1. Jiménez-Quevedo P, Angiolillo DJ, Bernardo E, Sabaté M. Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance? Catheter Cardiovasc Interv 2004;62:39-42.
2. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
3. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
4. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25:2331-2336.
5. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-227.
6. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responders: a pilot-study including 180 post-stroke patients. Thromb Res 1993;71: 397-403.
7. Buchanan MR, Hirsh J. Effect of aspirin on hemostasis and thrombosis. N Engl Reg Allergy Proc 1986;7:26-31.
8. Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100:789-792.
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responders: a pilot-study including 180 post-stroke patients. Thromb Res 1993;71: 397-403.
10. Mueller MR, Salat A, Stahgl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
11. Steinhubl SR, Varinasi JS, Goldberg L. Letters to editor. J Am Coll Cardiol 2003;42:1336-1337.
12. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
13. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-238.
14. Lau WC, Neer CJ, Watkins PB, Carville DG, Guyer KE, Bates ER. Clopidogrel nonresponders discovered during point-of-care platelet aggregation testing. J Am Coll Cardiol 2003;41(Suppl): 225A-226A.
15. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
16. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123-1125.
17. Gurbel PA, Bliden KP. Interpretation of platelet inhibition with clopidogrel, and effect on non-responders. J Thromb Haemost 2003;1:1318-1319.
18. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107: 2908-2913.
19. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
20. Wenawezer P, Hess OM, Meier B. Thienopyridines, a safety net with holes in it. Catheter Cardiovasc Interv 2003;59:303-304.
21. Theroux P, Angioi M, Gallo R, Ghitescu M, Frojmovic M. Interindividual variability in inhibition of platelet activation and aggregation by clopidogrel. J Thromb Haemost 2003;1(Suppl 1): 235.
22. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100(R) in peripheral angioplasty patients. Platelets 2002;13:493-497.
23. Mueller T, Haltmayer M, Poelz W, Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 2003;37:117-123.
24. Soffer D, Moussa I, Harjai KJ, Boura JA, Dixon SR, Grines CL, O'Neill WW, Roubin GS, Moses JW. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59:21-25.
25. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.